A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

Author： Verschraegen Claire   Kudelka Andrzej   Hu Wei   Vincent Monique   Kavanagh John   Loyer Evelyne   Bastien Luc   Duggal A.   Jager R.  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.53, Iss.1, 2004-01, pp. : 1-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma

By Rose P.G.   Gordon N.H.   Fusco N.   Fluellen L.   Rodriguez M.   Ingalls S.T.   Hoppel C.L.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 228-234

Elsevier

Access to resources Recommend Favorite

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite

Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite

Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer

By Garcia Agustin A.   Yessaian Anne   Pham Huyen   Facio Grace   Muderspach Laila   Roman Lynda  

Cancer Investigation, Vol. 30, Iss. 4, 2012-04 ,pp. : 295-299

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite